The news of JP Morgan maintaining an Overweight rating on UnitedHealth Group and lowering the price target from $595 to $562 may not have a significant short-term impact on the stock price. However, it indicates that the analyst still has a positive outlook on the company, which could influence investor sentiment. The lowered price target may reflect a more conservative outlook on the stock's potential upside.